| A phase 3 trial of bevacizumab in ovarian cancer TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, ... New England Journal of Medicine 365 (26), 2484-2496, 2011 | 2525 | 2011 |
| Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer MR Mirza, BJ Monk, J Herrstedt, AM Oza, S Mahner, A Redondo, ... New England Journal of Medicine 375 (22), 2154-2164, 2016 | 2395 | 2016 |
| Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials … A Du Bois, A Reuss, E Pujade‐Lauraine, P Harter, I Ray‐Coquard, ... Cancer 115 (6), 1234-1244, 2009 | 1784 | 2009 |
| A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer A Du Bois, HJ Lück, W Meier, HP Adams, V Mobus, S Costa, ... Journal of the National Cancer Institute 95 (17), 1320-1329, 2003 | 1672* | 2003 |
| Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial TC Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB ... Lancet 361, 2099-106, 2003 | 1389* | 2003 |
| ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease N Colombo, C Sessa, A Du Bois, J Ledermann, WG McCluggage, ... Annals of Oncology 30 (5), 672-705, 2019 | 1133* | 2019 |
| Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the … J Pfisterer, M Plante, I Vergote, A du Bois, H Hirte, AJ Lacave, U Wagner, ... Journal of Clinical Oncology 24 (29), 4699-4707, 2006 | 999* | 2006 |
| Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) GJS Rustin, M Quinn, T Thigpen, A Du Bois, E Pujade-Lauraine, ... Journal of the National Cancer Institute 96 (6), 487-488, 2004 | 947* | 2004 |
| Trastuzumab beyond progression in human epidermal growth factor receptor 2–positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study G von Minckwitz, A du Bois, M Schmidt, N Maass, T Cufer, FE de Jongh, ... Journal of Clinical Oncology 27 (12), 1999-2006, 2009 | 850 | 2009 |
| Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse E Pujade-Lauraine, U Wagner, E Aavall-Lundqvist, V Gebski, M Heywood, ... Journal of clinical oncology 28 (20), 3323-3329, 2010 | 704 | 2010 |
| Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study M Untch, M Rezai, S Loibl, PA Fasching, J Huober, H Tesch, I Bauerfeind, ... Journal of Clinical Oncology 28 (12), 2024-2031, 2010 | 680 | 2010 |
| Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ... Nature genetics 45 (4), 371-384, 2013 | 645 | 2013 |
| Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2–overexpressing breast … M Untch, PA Fasching, GE Konecny, S Hasmüller, A Lebeau, ... Journal of Clinical Oncology 29 (25), 3351-3357, 2011 | 632 | 2011 |
| A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms P Harter, J Sehouli, D Lorusso, A Reuss, I Vergote, C Marth, JW Kim, ... New England Journal of Medicine 380 (9), 822-832, 2019 | 611* | 2019 |
| Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial P Harter, A Bois, M Hahmann, A Hasenburg, A Burges, S Loibl, M Gropp, ... Annals of surgical oncology 13, 1702-1710, 2006 | 557 | 2006 |
| 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG … A Du Bois, M Quinn, T Thigpen, J Vermorken, E Avall-Lundqvist, ... Annals of oncology 16, viii7-viii12, 2005 | 551 | 2005 |
| Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer … G von Minckwitz, G Raab, A Caputo, M Schütte, J Hilfrich, JU Blohmer, ... Journal of clinical oncology 23 (12), 2676-2685, 2004 | 524 | 2004 |
| Incorporation of pazopanib in maintenance therapy of ovarian cancer A Du Bois, A Floquet, JW Kim, J Rau, JM Del Campo, M Friedlander, ... Journal of clinical oncology 32 (30), 3374-3382, 2014 | 482* | 2014 |
| GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer PDP Pharoah, YY Tsai, SJ Ramus, CM Phelan, EL Goode, K Lawrenson, ... Nature genetics 45 (4), 362-370, 2013 | 415 | 2013 |
| Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission … P Harter, J Sehouli, A Reuss, A Hasenburg, G Scambia, D Cibula, ... International Journal of Gynecologic Cancer 21 (2), 2011 | 368 | 2011 |
Philipp HarterEv. Kliniken Essen-Mitte, Essen, GermanyVerified email at kem-med.com
